NASDAQ:BEAM Beam Therapeutics Q1 2025 Earnings Report $16.76 -0.23 (-1.35%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$16.68 -0.09 (-0.51%) As of 06/20/2025 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Beam Therapeutics EPS ResultsActual EPS-$1.24Consensus EPS -$1.11Beat/MissMissed by -$0.13One Year Ago EPS-$1.21Beam Therapeutics Revenue ResultsActual Revenue$7.47 millionExpected Revenue$14.69 millionBeat/MissMissed by -$7.22 millionYoY Revenue Growth+1.40%Beam Therapeutics Announcement DetailsQuarterQ1 2025Date5/6/2025TimeBefore Market OpensConference Call DateTuesday, May 6, 2025Conference Call Time7:00AM ETUpcoming EarningsBeam Therapeutics' Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled on Wednesday, August 6, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Beam Therapeutics Earnings HeadlinesBeam Therapeutics Inc. (NASDAQ:BEAM) Receives $48.75 Consensus Target Price from BrokeragesJune 21 at 2:05 AM | americanbankingnews.comBeam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data ReleasesJune 20 at 2:48 PM | seekingalpha.comRevealed: Steve Jobs' Secret Project Comes to Life on July 21st?Did Steve Jobs Leave Behind a $25 Trillion Gift for America? In his final years, America's greatest innovator worked on a secretive project beyond Apple's walls— a vision he believed would transform our nation's economy and restore its global leadership. Insiders called it "extraordinary" and "a model for improving America." On July 21st, this hidden legacy could finally be revealed, unlocking what CNBC calls a "$25 trillion opportunity" for generations to come.June 22, 2025 | InvestorPlace (Ad)‘Life just changed.’ How Miami doctors use tech to treat cancer and sickle cellJune 19 at 2:46 PM | msn.comEli Lilly’s $1.3 Billion Bid Sends Verve Therapeutics Stock Soaring. What to Know.June 17, 2025 | msn.comBeam reports positive results from sickle cell disease treatmentJune 13, 2025 | msn.comSee More Beam Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Beam Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Beam Therapeutics and other key companies, straight to your email. Email Address About Beam TherapeuticsBeam Therapeutics (NASDAQ:BEAM), a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.View Beam Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Ahead Upcoming Earnings FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)Bank of America (7/14/2025)Wells Fargo & Company (7/14/2025)JPMorgan Chase & Co. (7/14/2025)Interactive Brokers Group (7/15/2025)America Movil (7/15/2025)Citigroup (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.